Compounds > guanine 7-oxide
Page last updated: 2024-11-13

guanine 7-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

guanine 7-oxide: from Streptomyces sp.; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135448994
SCHEMBL ID7705403
SCHEMBL ID9818039
SCHEMBL ID10964765
MeSH IDM0133672

Synonyms (25)

Synonym
guanine n7-oxide
nsc-353056
guanine, 7-oxide
guanine, n-7-oxide
7-hydroxyguanine
guanine 7-oxide
antibiotic pd 113876
antibiotic 3780
6h-purin-6-one, 2-amino-1,9-dihydro-, 7-oxide
2-amino-7-oxido-1,9-dihydropurin-7-ium-6-one
5227-68-9
NSC353056 ,
SCHEMBL7705403
6h-purin-6-one, 2-amino-1,7-dihydro-7-hydroxy-
16870-91-0
VWMKKTYDXHGESB-UHFFFAOYSA-N
2-amino-1,9-dihydro-6h-purin-6-one-7-oxide
SCHEMBL9818039
SCHEMBL10964765
DTXSID70168601
2-amino-6-oxo-6,9-dihydro-1h-purine 7-oxide
2-amino-7-hydroxy-1h-purin-6-one
pd-113876
VV6PV58VBZ
2-amino-6-oxo-6,9-dihydro-1h-purin-7-ium-7-olate

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Guanine 7-N-oxide was shown to have synergistic activity in combination with neplanocin A against a rhabdovirus, infectious hematopoietic necrosis virus (IHNV), as reported previously."( The synergism of nucleoside antibiotics combined with guanine 7-N-oxide against a rhabdovirus, infectious hematopoietic necrosis virus (IHNV).
Hasobe, M; Isono, K; Saneyoshi, M, 1986)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (72.73)18.7374
1990's2 (18.18)18.2507
2000's0 (0.00)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uridine
[no description available]		3.3110uridinesdrug metabolite;
fundamental metabolite;
human metabolite
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		3.5120adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
neplanocin a
neplanocin A: neplanocins are antitumor antibiotics & carbocyclic analogs of purine nucleosides from Ampullarilla regularis A11079; see also neplanocin B, neplanocin C, neplanocin D & neplanocin F; structure in first source; a potent inhibitor of S-adenosylhomocysteine hydrolase		1.9610
phosmidosine
phosmidosine: from Streptomyces sp. RK-16; structure given in first source		3.3110
nikkomycin
[no description available]		3.3110
ascamycin
ascamycin: from a Streptomyces species; structure given in first source		3.3110
guanine
[no description available]		9.861102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Leukemia
[description not available]		02.3820
Leukemia L 1210
[description not available]		02.3720
Experimental Neoplasms
[description not available]		02.3720